NRx Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
NRx Pharmaceuticals, Inc. carries a market capitalization of 361,784.00, placing it among publicly traded companies globally. Its enterprise value stands at -24.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 361,784.00 |
| Enterprise Value | -24.83M |
Share Statistics
NRx Pharmaceuticals, Inc. currently has 43.16M shares outstanding.
| Shares Outstanding | 43.16M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -3.60 |
| P/TBV Ratio | -0.22 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 21.47 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
NRx Pharmaceuticals, Inc. maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.94, indicating conservative leverage, while an interest coverage ratio of -16.97 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.86 |
| Quick Ratio | 0.79 |
| Debt / Equity | -732.94 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | -16.97 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -120.42 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 90.43 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
NRx Pharmaceuticals, Inc.'s stock has declined approximately -82.61934% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | -82.61934% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.06 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -19.42M, while operating income came in at -19.90M.
| Revenue | 3.39M |
| Gross Profit | 1.58M |
| Operating Income | -19.90M |
| Pretax Income | -23.48M |
| Net Income | -23.48M |
| EBITDA | -19.42M |
| EBIT | -19.90M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
NRx Pharmaceuticals, Inc. holds 26.69M in cash and equivalents against 1.25M in total debt, resulting in a net debt position of -26.27M. Total book value stands at -170,000.00, with working capital of -4.72M providing operational flexibility.
| Cash & Cash Equivalents | 26.69M |
| Total Debt | 1.25M |
| Net Debt | -26.27M |
| Equity (Book Value) | -170,000.00 |
| Book Value Per Share | 0.00 |
| Working Capital | -4.72M |
Cash Flow
NRx Pharmaceuticals, Inc. produced -19.77M in operating cash flow over the past twelve months.
| Operating Cash Flow | -19.77M |
| Capital Expenditures | N/A |
| Free Cash Flow | -19.77M |
| FCF Per Share | N/A |
Margins
NRx Pharmaceuticals, Inc. operates with a gross margin of 46.64, reflecting its pricing power and cost economics. The operating margin of -586.24 and net profit margin of -691.81 provide insight into operational efficiency.
| Gross Margin | 46.64 |
| Operating Margin | -586.24 |
| Pretax Margin | -691.81 |
| Profit Margin | -691.81 |
| EBITDA Margin | -572.07 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7,711.15 |
| FCF Yield | N/A |
Scores
NRx Pharmaceuticals, Inc. posts an Altman Z-Score of -16.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -16.56 |